Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs SOLAI Limited (SLAI) Price & Performance

Ginkgo Bioworks Holdings IncTrade
SOLAI LimitedTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs SOLAI Limited — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 30.3× SOLAI Limited's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.

DNASLAI
Market Cap
$505.73M$16.69M
Sector
HealthTechnology
52-Week High
$16.14$26.74
52-Week Low
$5.48$2.74
Enterprise Value
$607.68M$16.33M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.

DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.

SOLAI Limited

SLAI trades at $3.72 with no recent price movement, showing mixed technical signals despite a bullish overall rating. The company faces severe financial distress with negative profit margins (-134.63% net income margin) and declining revenue, compounded by NYSE delisting proceedings initiated in July 2026. Recent corporate actions include a 7:1 reverse stock split completed in July 2026 and the acquisition of a 51% stake in NEURALAND, signaling strategic shifts amid operational challenges.

The outlook remains highly speculative with significant execution and liquidity risks. While technical indicators suggest potential short-term momentum, fundamental weaknesses and delisting uncertainty create substantial downside risk. Investors should approach with caution given the company's negative profitability and regulatory challenges.

Returns comparison

Trailing returns across standard periods

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About SOLAI Limited

SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.

Read more on SLAI